RONA APOC3
Alternative Names: RONA-APOC3Latest Information Update: 05 Jan 2024
At a glance
- Originator Rona Therapeutics
- Class Antihyperlipidaemics; Small interfering RNA
- Mechanism of Action APOC3-protein-expression-inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypertriglyceridaemia
Most Recent Events
- 10 Nov 2023 Preclinical trials in Hypertriglyceridaemia in China (SC)
- 10 Nov 2023 Pharmacodynamics, pharmacokinetic and adverse events data from preclinical trial in Hypertriglyceridaemia presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases (ASLD-2023)